Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC

Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.

Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients MSI-H/ dMMR metastatic colorectal cancer.

Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing 

®. Gina joined the company in 2015 and has held various positions on 

Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Dr. Jackson is a certified oncology and bone marrow transplant clinical nurse specialist with clinical expertise in hematology/stem cell transplantation/cellular therapy. She is currently unit director–providing oversight of the clinical and fiscal operations of an inpatient hematology unit. Dr. Jackson is also a member of the National Association of Clinical Nurse Specialist, American Asociation of California Nurse Leaders, and the Oncology Nurses Society.

Oncology nurses are paramount to the success of patients, especially through their work on clinical trials.

The Evolving Role of the Oncology Nurse in Clinical Trials

Randi Kihnel, MSN, APRN, ACCNS-AG is an advanced practice nurse who works in GI Medical Oncology at Ochsner MD Anderson Cancer Center.

Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.

Case Study: Bridging the Gap for Patients With Metastatic CRC

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

Luspatercept led to durable red blood cell transfusion independence and early OS signals in ESA-naive, lower-risk MDS, per updated COMMANDS data.

Luspatercept Improves Transfusion Independence in Lower-Risk MDS

SVR10 at week 12 with pacritinib was linked to longer overall survival in patients with myelofibrosis and thrombocytopenia.

Pacritinib SVR Tied to OS Benefit in Thrombocytopenic Myelofibrosis

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment reduced daily dosages over 12 months.

As-Expected Ruxolitinib Starting Dose Outperforms Lower Dosage in Myelofibrosis

Clinical response rates were higher in patients with phlebotomy-dependent polycythemia vera who received rusfertide than in those who received placebo.

Rusfertide Plus SOC Reaches Response End Point in Phlebotomy-Dependent PV

Ropeginterferon alfa-2b showed superior efficacy over anagrelide in the SURPASS-ET trial for essential thrombocythemia, with higher durable response rates and greater JAK2 allele burden reduction.

Ropeginterferon Alfa-2b Effective in Phase 3 Essential Thrombocythemia Trial

Kathryn Johnson, DNP, MSc, FNP-BC, speaks on the role of nurses clinical trials in MPNs and how treatment has evolved

Kathryn Johnson, DNP, MSc, FNP-BC, speaks on clinical trials in MPNs

Educating patients on the risks and benefits of clinical trials is a part of the pipeline for better treatment options in myeloproliferative neoplasms (MPNs) in which nurses can engage, said a nurse practitioner.

For patients with MPNs, clinical trials have paved the way for better treatment outcomes, increasing options vastly within a short amount of time. In an interview with 

, Kathryn Johnson, DNP, MSc, FNP-BC, spoke about the importance of the development of these options and the nurses’ role in making them possible.

As Johnson, a clinical program manager at Icahn School of Medicine at Mount Sinai New York, outlined, nurses can play a key part in informing patients on what to expect on clinical trials. She advised not only being prepared with information patients should know but making time for patients to air their concerns and ask questions.

Johnson added that in the time that she has been working in oncology, multiple advancements have been made in the treatment of 

. She expects this trend to continue in the coming years.

A thorough presentation of the risks and benefits is fundamental of good clinical practice for patients going on to clinical trials. So, when we do consenting, we make sure that patients have ample time for questions and an opportunity to 

It doesn’t stop there, though. Throughout the course of their time on trial, however long that may be, we are constantly checking in to make sure [that] not only are we assessing the risk and benefit from the trial perspective, but also with the specific needs of the patients.

I think being positioned in a major academic institution by nature presents us with a lot of opportunities to give patients different pathways for care. So, we routinely review the list of patients who we have and make sure that we’re going through what’s working for them, what’s not working for them, and then establishing a good connection to our network of providers in the community, so that they know if they want to look at something a little bit differently, they can come to us.

I haven’t been in this field all that long, but just in the time that I’ve been doing this, I’ve already seen tremendous changes in what’s available to help patients. Stem cell transplant is the only known cure for MPNs, but I’m optimistic that in my lifetime that will change.

One of my favorite graphs from a slide that I’ve presented is one that shows how much things have changed just in the past 15 years. We went from having zero [Janus kinase] inhibitors to now there are 4, and that’s, for myelofibrosis, transformative. We can help patients live their lives better with more therapies on the market.

I’m very excited about the clinical trials that we have going on right now, and I expect that there will continue to be a lot more dedicated, brilliant, scientific minds working on even more options in the future. I think [there is the] potential for combination therapy. I’m optimistic that curative therapy will be available. I think there’s a lot coming down the pipeline.

This transcript has been edited for clarity and conciseness.

Clinical trials can provide patients with myeloproliferative neoplasms expanded treatment options.

Clinical Trials Can Open Doors for Patients With Myeloproliferative Neoplasms

Oncology nurses and APPs should prioritize active listening and deeper patient engagement to build trusting, long-term relationships with patients with MPNs.

Building a Foundation of Trust in Patients With MPNs 

For oncology nurses and APPs caring for patients with chronic conditions like MPNs, fostering a comfortable environment begins with active listening that extends beyond clinical data, an expert said.

Understanding the patient's life outside the exam room—their sources of joy and their personal challenges—is essential for providing holistic care. Given the nature of MPNs, these providers often develop long-term relationships with patients, sometimes seeing them more frequently than they see their own families. Therefore, prioritizing the establishment of trusting relationships through deeper patient engagement is paramount for optimizing care and support throughout the patient's journey.

Oncology Nursing News spoke with Kathryn Johnson, DNP, MSc, FNP-BC, to learn more about how connections like these can really benefit patients with MPNs.

Johnson is a Clinical Program Manager at Icahn School of Medicine at Mount Sinai New York.

I think the best thing to do to help people feel at ease is to listen, not just superficial listening, but really active listening. I love to learn about my patients and who they are outside of the exam room, because when they come to us, it's such a small part of their lives. Understanding what brings them joy, what struggles they're having beyond what their blood counts show, is so important to helping making sure that we're doing holistic care for our patients.

MPNs are chronic disorders, which means that we actually get to establish really lovely, long-term relationships with our patients. I have patients that I've seen over the last 5 years once or twice a month, which is more often than I even get to see my own family in Virginia. So, I think making sure, again, that we're building those long-term relationships with a good foundation of trust by getting to know the patients on a deeper level, is really important.

This transcript has been edited for clarity and conciseness

Myeloproliferative Neoplasms

Latest News

Latest Conference Coverage